Navigation Links
Neuralstem files FDA application for first drug therapy
Date:11/17/2010

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

"This marks more than just a significant milestone for the company: we believe our compound represents the next generation of antidepressant treatment based on a new mechanism of action that may, for the first time, fundamentally modify the disease," said Neuralstem President & CEO Richard Garr. "NSI-189 also validates Neuralstem's proprietary neural stem cell screening approach as a source for discovering novel compounds that affect complex stem cell biology rather than a single molecular target."

"The antidepressants that are available today are based on the theory of serotonin deficiency," explained Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "NSI-189 is based on a new theory that chronic exposure to stress hormones can inhibit the growth of new neurons in certain regions of the brain. This can lead to hippocampal atrophy and depression. We believe that this neurogenic approach to brain self-repair may be applicable in multiple diseases including: Alzheimer's disease, mild cognitive impairment, dementia, schizophrenia, cognitive complications from diabetes, post-traumatic stress syndrome and traumatic brain injury, all of which are indications that the company intends to pursue with this new class of drugs."

About NS-189: Stimulating Neurogenesis To Address Central Nervous System Conditions

NS-189 is the first in a class of compounds that Neuralstem plans to develop into orally administered dru
'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Neuralstem updates clinical trial progress
2. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
3. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
4. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
5. Neuralstem updates ALS clinical trial progress
6. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
7. Facebook Profiles Dont Stretch the Truth
8. Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009
9. Justice Department Files for Immediate Relief Regarding Conditions at Conway Human Development Center, in Conway, Arkansas
10. Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement
11. Scilabs Nutraceuticals Inc., Files Multimillion Dollar Suit Against Naturade for Fraudulent Business Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... New York (PRWEB) September 18, 2014 ... lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s ... have all claims filed on behalf of out-of-state ... motions filed on September 11th, the defendants maintain ... claims contained in the lawsuits have no connection ...
(Date:9/18/2014)... 18, 2014 Memorial Cardiac and ... this week by performing the first ever, adult heart ... Network for Organ Sharing) approval to launch the adult ... only two programs in South Florida. , The ... Enrique Gongora, Medical Director of the Adult Heart ...
(Date:9/18/2014)... people become more physically vulnerable during bereavement, new research ... during bereavement changes with age, British researchers say. As ... likely to have weakened immune systems and develop infections, ... months after loss, we can suffer from reduced neutrophil ... blood cell and as such are essential at combating ...
(Date:9/18/2014)... September 18, 2014 One of the ... medical transport industry, ShandsCair Flight Program’s new ... Inc . (AHI) at the Air Medical Transport Conference ... delivered and placed into service ShandsCair EC155 and the ... be displayed at AMTC highlight Airbus Helicopters broad, industry ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Daily supplements of selenium ... the development of age-related cataracts among men, a new ... one or both could help prevent cataracts. To investigate ... and Harvard Medical School in Boston, and his colleagues ... and vitamin E. The trial was initially designed to ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2
... ... to Sonitor’s Ultrasound RTLS Technology Platform strengthen further the technology’s position as the ... ... Sonitor Technologies, the world leader in ultrasound-based real time locating systems for hospitals ...
... ... ... , ... , , , ...
... patients who regularly received massages averaging 14 minutes or more ... over four weeks, according to results of a study reported ... Society. In the study, sponsored by the National Cancer ... program to provide massage to patients at home. The multi-ethnic ...
... The introduction of prostate-specific antigen (PSA) testing as a screening ... beginning of the 1990s drastically increased the detection of PCa. ... men with PCa. To assess the risk of suicide among ... study was carried out in Sweden. The results are published ...
... Copenhagen, led by postdoc Luke Holman of the Center for ... B , published on the 24 February 2010, that ant ... Often, an ant colony has more than one queen. Multiple ... increasing the chance the colony will survive the hazardous first ...
... ... wristbands market with line of ready-to-ship LaserBand® products that can be instantly priced and ... ... in providing a complete range of printed products and services, today announced the launch ...
Cached Medicine News:Health News:Sonitor Technologies Announces New Staff Tag and Battery Powered Ultrasound Receiver 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 3Health News:Family members reduce stress in advanced cancer patients with 14 minute massages 2Health News:Plotting and treachery in ant royal families 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 3
(Date:9/18/2014)... 18, 2014 MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... that it has entered into a distribution agreement ... provide its dehydrated human amnion/chorion membrane ("dHACM") allograft ... on a private label basis. The ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  Halozyme ... announced that the U.S. Food and Drug Administration ... enrollment and dosing of PEGPH20 in SWOG,s ongoing ... designed to evaluate Halozyme,s investigational drug PEGPH20 (PEGylated ... chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.  ...
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to the position of  Senior Director of Clinical Development. ... Mr. James has established and led successful global clinical ... , to facilitate the clinical development of numerous ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 2Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 3Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 4Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 11China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 12China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 13China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 14China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 15China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 16China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 17China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 18China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 19China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 20China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 21China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 22China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 23China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 24China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 25China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 26China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 27
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: